Apyx Medical Inc

Apyx Medical Inc(APYX)股票分析

$3.060

+0.555 (+18.15%)收盘时

Loading chart…
最高
3.107
开盘
2.600
成交量加权均价
2.91
成交量
995.02K
市值
48.85M
最低
2.575
成交额
2.90M
企业价值/息税折旧摊销前利润(TTM)
-15.53

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

AI 分析 of Apyx Medical Inc (APYX)

买入

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

估值指标

Apyx Medical Inc(APYX)当前预期市盈率为 72.46,5 年平均预期市盈率为 5.82。

预期市盈率

严重高估
5 年均值 P/E
5.82
当前P/E
72.46
高估
36.80
低估
-25.16

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-9.40
当前EV/EBITDA
-15.53
高估
30.40
低估
-49.21

预期市销率

合理
5 年均值 P/S
2.49
当前P/S
1.65
高估
4.41
低估
0.56

Alphio AI 对 APYX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%APYX

$1.80

情景价格

基

基准

基准 · 50%APYX

$1.74

情景价格

悲

悲观

悲观 · 25%APYX

$1.70

情景价格

持有 APYX 的大户

N

Nantahala Capital Management, LLC

+ 持有APYX

+10.21%

3个月收益率

事件时间线

2026-11-05 (ET)

08:31:00

Company Expects Gross Margins of 63% to 65%

08:31:00

AYON Reports Q3 Revenue of $14.03M, 17% Growth

2026-09-29 (ET)

08:30:00

Apyx Medical Releases Renuvion Study Results, Significant Skin Quality Improvement

2026-08-06 (ET)

17:00:00

Company Expects Operating Expenses Below $45 Million for 2026

17:00:00

AYON Reports Q2 Revenue of $13.88M, Beating Expectations

资讯

APYX 常见问题 —— 由 Alphio AI 解答

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易